← All trials
NCT05851014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2022
- Primary completion
- Jan 30, 2026
- Completion date
- Jan 30, 2027
- First posted
- May 9, 2023
- Last posted
- May 9, 2023
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genor BioPharma Co., Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.